FAS and lung cancer: Bortezomib upregulated TRAILR-2 but not TRAILR-1 receptors cell surface expression in lung cancer cell lines [35] and significantly increased the transcript expression of TRAILR-1, TRAILR-2 and Fas in colorectal tumor cells [36].